Equity Investment Corp Has $96.76 Million Stake in Sanofi (NASDAQ:SNY)

Equity Investment Corp lessened its stake in Sanofi (NASDAQ:SNY) by 0.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 1,945,602 shares of the company’s stock after selling 6,743 shares during the period. Sanofi comprises 2.7% of Equity Investment Corp’s investment portfolio, making the stock its 15th biggest position. Equity Investment Corp’s holdings in Sanofi were worth $96,755,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Cardinal Capital Management increased its stake in shares of Sanofi by 0.3% in the 4th quarter. Cardinal Capital Management now owns 58,854 shares of the company’s stock valued at $2,927,000 after buying an additional 201 shares during the period. Daiwa Securities Group Inc. increased its stake in shares of Sanofi by 3.4% in the 4th quarter. Daiwa Securities Group Inc. now owns 6,541 shares of the company’s stock valued at $325,000 after buying an additional 216 shares during the period. Gallacher Capital Management LLC increased its stake in shares of Sanofi by 4.5% in the 3rd quarter. Gallacher Capital Management LLC now owns 5,715 shares of the company’s stock valued at $307,000 after buying an additional 245 shares during the period. Rise Advisors LLC boosted its position in shares of Sanofi by 98.4% in the 4th quarter. Rise Advisors LLC now owns 506 shares of the company’s stock worth $25,000 after purchasing an additional 251 shares during the last quarter. Finally, True Wealth Design LLC boosted its position in shares of Sanofi by 1.9% in the 3rd quarter. True Wealth Design LLC now owns 13,828 shares of the company’s stock worth $742,000 after purchasing an additional 260 shares during the last quarter. 10.04% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on SNY shares. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. Morgan Stanley started coverage on Sanofi in a research report on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 price target on the stock. Finally, TheStreet lowered Sanofi from a “b” rating to a “c” rating in a research report on Friday, February 9th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, Sanofi presently has an average rating of “Moderate Buy” and a consensus price target of $55.00.

Sanofi Trading Down 0.3 %

SNY stock traded down $0.15 during midday trading on Friday, hitting $48.67. 838,711 shares of the company’s stock were exchanged, compared to its average volume of 2,464,985. The stock’s fifty day moving average price is $48.20 and its 200-day moving average price is $48.11. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.27. The company has a market cap of $123.12 billion, a PE ratio of 24.46, a price-to-earnings-growth ratio of 1.36 and a beta of 0.61. Sanofi has a one year low of $42.63 and a one year high of $55.72.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, April 25th. The company reported $0.96 earnings per share for the quarter, hitting the consensus estimate of $0.96. The firm had revenue of $11.36 billion for the quarter, compared to analyst estimates of $11.75 billion. Sanofi had a return on equity of 19.69% and a net margin of 10.52%. Research analysts predict that Sanofi will post 4.12 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The firm also recently announced an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be issued a dividend of $1.478 per share. The ex-dividend date is Thursday, May 9th. This is a positive change from Sanofi’s previous annual dividend of $1.38. This represents a yield of 2.98%. Sanofi’s payout ratio is currently 74.37%.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.